Results from Phase IIIb Study of POMALYST®/IMNOVID® (pomalidomide) Plus Low-Dose dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Presented at ASH

Results from Phase IIIb Study of POMALYST®/IMNOVID® (pomalidomide) Plus Low-Dose dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Presented at ASH